$7.52
At close: Apr 17 EDT
$7.50
-0.02-0.27%
Pre-Market: 4:04 AM EDT
Comments
Loading...
Cormedix Analyst Ratings and Price Targets | NASDAQ:CRMD | Benzinga
Cormedix Inc has a consensus price target of $15.25 based on the ratings of 8 analysts. The high is $19 issued by JMP Securities on April 9, 2024. The low is $12 issued by Needham on April 9, 2025. The 3 most-recent analyst ratings were released by Needham, D. Boral Capital, and RBC Capital on April 9, 2025, April 8, 2025, and March 26, 2025, respectively. With an average price target of $13 between Needham, D. Boral Capital, and RBC Capital, there's an implied 73.33% upside for Cormedix Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
D. Boral Capital
RBC Capital
Leerink Partners
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Cormedix
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 60% | Needham | Serge Belanger64% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 100% | D. Boral Capital | Jason Kolbert41% | $15 → $15 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | 60% | RBC Capital | Gregory Renza45% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 03/26/2025 | Buy Now | 60% | Needham | Serge Belanger64% | $18 → $12 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | 100% | D. Boral Capital | Jason Kolbert41% | $15 → $15 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 140% | Leerink Partners | Roanna Ruiz34% | → $18 | Initiates | → Outperform | Get Alert |
| 03/05/2025 | Buy Now | 100% | D. Boral Capital | Jason Kolbert41% | $15 → $15 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | 100% | D. Boral Capital | Jason Kolbert41% | $15 → $15 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | 100% | D. Boral Capital | Jason Kolbert41% | → $15 | Initiates | → Buy | Get Alert |
| 12/19/2024 | Buy Now | 60% | RBC Capital | Gregory Renza45% | $11 → $12 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 140% | Needham | Serge Belanger64% | $10 → $18 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | 126.67% | Truist Securities | Joon Lee76% | $12 → $17 | Maintains | Buy | Get Alert |
| 08/26/2024 | Buy Now | 73.33% | Rodman & Renshaw | Brandon Folkes39% | → $13 | Initiates | → Buy | Get Alert |
| 08/15/2024 | Buy Now | 20% | RBC Capital | Gregory Renza45% | $9 → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 33.33% | Needham | Serge Belanger64% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2024 | Buy Now | 60% | Truist Securities | Joon Lee76% | $14 → $12 | Maintains | Buy | Get Alert |
| 06/19/2024 | Buy Now | 33.33% | Needham | Serge Belanger64% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 33.33% | Needham | Serge Belanger64% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 33.33% | Needham | Serge Belanger64% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 153.33% | JMP Securities | Jason Butler51% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/13/2024 | Buy Now | 20% | RBC Capital | Gregory Renza45% | $10 → $9 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 33.33% | Needham | Serge Belanger64% | $10 → $10 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 86.67% | Truist Securities | Joon Lee76% | $18 → $14 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 33.33% | Needham | Serge Belanger64% | $12 → $10 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 33.33% | RBC Capital | Gregory Renza45% | $6 → $10 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | 140% | Truist Securities | Joon Lee76% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | Buy Now | 153.33% | JMP Securities | Jason Butler51% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/10/2023 | Buy Now | -20% | RBC Capital | Gregory Renza45% | → $6 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 60% | Needham | Serge Belanger64% | $13 → $12 | Maintains | Buy | Get Alert |
| 06/21/2023 | Buy Now | 73.33% | Needham | Serge Belanger64% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | Buy Now | 153.33% | JMP Securities | Jason Butler51% | $16 → $19 | Maintains | Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | 73.33% | Needham | Serge Belanger64% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2023 | Buy Now | 113.33% | JMP Securities | Jason Butler51% | → $16 | Reiterates | → Market Outperform | Get Alert |
| 03/31/2023 | Buy Now | 73.33% | Needham | Serge Belanger64% | → $13 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 73.33% | Needham | Serge Belanger64% | → $13 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 113.33% | JMP Securities | Roy Buchanan34% | $14 → $16 | Maintains | Market Perform | Get Alert |
| 11/11/2022 | Buy Now | 73.33% | Needham | Serge Belanger64% | $12 → $13 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | 113.33% | Truist Securities | Joon Lee76% | $27 → $16 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 86.67% | JMP Securities | Jason Butler51% | $19 → $14 | Maintains | Market Outperform | Get Alert |
| 08/09/2022 | Buy Now | 60% | Needham | Serge Belanger64% | $20 → $12 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cormedix (CRMD) stock?
The latest price target for Cormedix (NASDAQ:CRMD) was reported by Needham on April 9, 2025. The analyst firm set a price target for $12.00 expecting CRMD to rise to within 12 months (a possible 60.00% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cormedix (CRMD)?
The latest analyst rating for Cormedix (NASDAQ:CRMD) was provided by Needham, and Cormedix reiterated their buy rating.
When was the last upgrade for Cormedix (CRMD)?
There is no last upgrade for Cormedix
When was the last downgrade for Cormedix (CRMD)?
There is no last downgrade for Cormedix.
When is the next analyst rating going to be posted or updated for Cormedix (CRMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Cormedix (CRMD) correct?
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a reiterated with a price target of $12.00 to $12.00. The current price Cormedix (CRMD) is trading at is $7.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
